- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Erica Mayer on Improving Patient Adherence to Hormonal Therapies
Listening to patient concerns and issues and communicating with them can really help providers keep patients with breast cancer adherent to their hormonal therapies, said Erica Mayer, MD, MPH, assistant professor, medicine, Harvard Medical School.
Listening to patient concerns and issues and communicating with them can really help providers keep patients with breast cancer adherent to their hormonal therapies, said Erica Mayer, MD, MPH, assistant professor, medicine, Harvard Medical School.
Transcript
What tools can physicians employ to improve adherence of hormonal therapies among patients with breast cancer?
I think, you know, a major tool that providers can do to help maintain patients on therapy is communication and listening to how patients are doing assessing their symptoms and acting, and if a patient needs to take a short break, if we need to rotate from one aromatase inhibitor to another, if we need to explore a supportive care medicine, or having a patient try acupuncture exercise—there's a lot of strategies to use.
But I think the most important thing is if a patient is unhappy or uncomfortable or feels like they, they just can't do it, we need to know, and we need to work on that together, rather than not hearing each other and then having somebody stop therapy early.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Camlipixant May Benefit Patients With High-Burden RCC
June 25th 2025A phase 2a trial of camlipixant, a selective P2X3 receptor antagonist, found that while the drug did not significantly reduce cough frequency in the overall population with refractory chronic cough, it produced meaningful improvements in patients with a higher baseline cough burden.
Read More
